|Articles|August 22, 2022

Research and Markets Releases 2022 Digital Biomarkers Drug Development Market Report

The "Growth Opportunities for Digital Biomarkers in Drug Development" report has been added to ResearchAndMarkets.com's offering. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact.

Key topics covered:

Strategic Imperatives
Growth Opportunity Analysis
Growth Opportunity Analysis - Neurology
Growth Opportunity Analysis - Oncology
Regulatory Landscape
Industry Assessment and Analysis
Patent Landscape
Growth Opportunity Universe

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

A Shot in the Arm to Traditional Vaccine Trial Strategy

ByAsad Khan

June 5th 2026

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ByLiz Beatty,Andy Studna, Senior Editor

June 5th 2026

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

ByAndy Studna, Senior Editor

June 5th 2026

© putilov_denis - © putilov_denis - stock.adobe.com

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

ByMarcela Roy, MA, Lauren Crooks, MSc, Graham Ellis, MD, Alan Kott, MUDR, Dawie Wessels, MD, Elias Ketiar, MD, MRCP

June 4th 2026

For pharmaceutical and life sciences organizations, the strategic imperative is clear: begin immediately with foundation building, scale systematically with measurable milestones, and transform comprehensively toward AI-native data operations. Credit: Stock.Adobe.com/tippapatt.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ByPartha Anbil,Partha Khot

June 4th 2026

Research and Markets Releases 2022 Digital Biomarkers Drug Development Market Report

Related Content

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

A Shot in the Arm to Traditional Vaccine Trial Strategy